Redmile Group LLC increased its holdings in Epizyme Inc (NASDAQ:EPZM) by 15.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,694,020 shares of the biopharmaceutical company’s stock after purchasing an additional 1,056,742 shares during the quarter. Epizyme accounts for 2.8% of Redmile Group LLC’s investment portfolio, making the stock its 10th biggest position. Redmile Group LLC owned 0.08% of Epizyme worth $95,329,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Exane Derivatives acquired a new position in Epizyme in the first quarter valued at approximately $84,000. Legal & General Group Plc raised its stake in shares of Epizyme by 16.9% in the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 1,455 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Epizyme during the fourth quarter valued at $76,000. BNP Paribas Arbitrage SA grew its stake in Epizyme by 992.8% in the first quarter. BNP Paribas Arbitrage SA now owns 13,627 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 12,380 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. boosted its stake in shares of Epizyme by 10.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,691 shares of the biopharmaceutical company’s stock worth $170,000 after acquiring an additional 1,293 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ EPZM opened at $11.63 on Monday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -6.76 and a beta of 2.72. Epizyme Inc has a fifty-two week low of $5.14 and a fifty-two week high of $16.10. The company has a current ratio of 12.55, a quick ratio of 12.55 and a debt-to-equity ratio of 0.03.
A number of research analysts have commented on EPZM shares. Cowen reiterated a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research report on Tuesday, February 26th. Wedbush reissued an “outperform” rating and set a $21.00 price target on shares of Epizyme in a research report on Wednesday, June 12th. BidaskClub cut Epizyme from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Tuesday, April 30th. Finally, HC Wainwright set a $25.00 price objective on shares of Epizyme and gave the company a “buy” rating in a research report on Friday, May 31st. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Epizyme currently has an average rating of “Buy” and a consensus price target of $18.90.
In related news, CEO Robert B. Bazemore sold 2,074 shares of the business’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $12.10, for a total value of $25,095.40. Following the sale, the chief executive officer now owns 87,068 shares of the company’s stock, valued at $1,053,522.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 16.60% of the company’s stock.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
See Also: Margin
Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.